Top-Rated StocksTop-RatedNASDAQ:NTRA Natera (NTRA) Stock Price, News & Analysis $112.90 -4.60 (-3.91%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$110.57▼$118.5250-Day Range$97.75▼$123.9852-Week Range$36.90▼$124.83Volume946,364 shsAverage Volume1.38 million shsMarket Capitalization$13.86 billionP/E RatioN/ADividend YieldN/APrice Target$120.07 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Natera alerts: Email Address Natera MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside6.3% Upside$120.07 Price TargetShort InterestHealthy6.21% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.77Based on 6 Articles This WeekInsider TradingSelling Shares$10.21 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.03) to ($0.99) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.65 out of 5 starsMedical Sector614th out of 910 stocksMedical Laboratories Industry16th out of 18 stocks 2.5 Analyst's Opinion Consensus RatingNatera has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 15 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNatera has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Natera's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.21% of the outstanding shares of Natera have been sold short.Short Interest Ratio / Days to CoverNatera has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Natera has recently decreased by 9.72%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNatera does not currently pay a dividend.Dividend GrowthNatera does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NTRA. Previous Next 2.7 News and Social Media Coverage News SentimentNatera has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Natera this week, compared to 7 articles on an average week.Search Interest18 people have searched for NTRA on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Natera to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Natera insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,205,064.00 in company stock.Percentage Held by InsidersOnly 7.60% of the stock of Natera is held by insiders.Percentage Held by Institutions99.90% of the stock of Natera is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Natera's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Natera are expected to grow in the coming year, from ($2.03) to ($0.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Natera is -36.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Natera is -36.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNatera has a P/B Ratio of 16.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Natera's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsWhat is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …Find out details on these three critical Nvidia partners immediately. About Natera Stock (NASDAQ:NTRA)Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.Read More NTRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NTRA Stock News HeadlinesAugust 20, 2024 | insidertrades.comNatera, Inc. (NASDAQ:NTRA) CEO Sells $663,874.53 in StockAugust 17, 2024 | insidertrades.comNatera, Inc. (NASDAQ:NTRA) Insider Jonathan Sheena Sells 12,000 SharesSeptember 7, 2024 | Weiss Ratings (Ad)What is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …August 15, 2024 | insidertrades.comNatera, Inc. (NASDAQ:NTRA) Insider Sells $307,314.00 in StockSeptember 7 at 9:38 AM | finance.yahoo.comWhat Makes Natera (NTRA) an Investment Bet?September 3, 2024 | finance.yahoo.comNatera (NTRA) Rose After Revenues And Profit Margins Beat EstimatesSeptember 1, 2024 | msn.comBillionaire Stan Druckenmiller Is Betting On Natera, Inc. (NTRA)August 29, 2024 | americanbankingnews.comNatera (NASDAQ:NTRA) Downgraded to Sell at StockNews.comSeptember 7, 2024 | Weiss Ratings (Ad)What is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …August 29, 2024 | americanbankingnews.comCanaccord Genuity Group Raises Natera (NASDAQ:NTRA) Price Target to $145.00August 29, 2024 | americanbankingnews.comNatera, Inc. (NASDAQ:NTRA) Receives $119.07 Consensus Target Price from BrokeragesAugust 29, 2024 | msn.comNatera, Inc. (NTRA): Among Morgan Stanley’s Highest Conviction StocksAugust 28, 2024 | finance.yahoo.comNatera to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceAugust 28, 2024 | msn.comNatera, Inc. (NTRA): Among Morgan Stanley's Highest Conviction StocksAugust 20, 2024 | fool.comCathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtAugust 16, 2024 | uk.investing.comNatera co-founder Sheena Jonathan sells over $300k in company stockAugust 15, 2024 | seekingalpha.comNatera: Focus On Signatera And H1 2024 ResultsAugust 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Natera (NTRA) and Disc Medicine (IRON)See More Headlines Receive NTRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:NTRA CUSIPN/A CIK1604821 Webwww.natera.com Phone(650) 249-9090FaxN/AEmployees3,293Year FoundedN/APrice Target and Rating Average Stock Price Target$120.07 High Stock Price Target$150.00 Low Stock Price Target$70.00 Potential Upside/Downside+6.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($3.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-434,800,000.00 Net Margins-21.47% Pretax Margin-21.35% Return on Equity-36.74% Return on Assets-19.90% Debt Debt-to-Equity Ratio0.34 Current Ratio4.14 Quick Ratio4.01 Sales & Book Value Annual Sales$1.36 billion Price / Sales10.19 Cash FlowN/A Price / Cash FlowN/A Book Value$6.76 per share Price / Book16.70Miscellaneous Outstanding Shares122,803,000Free Float113,470,000Market Cap$13.86 billion OptionableOptionable Beta1.53 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesDr. Matthew Rabinowitz Ph.D. (Age 51)Co-Founder & Executive Chairman Comp: $441.58kMr. Steven Leonard Chapman (Age 45)CEO & Director Comp: $1.15MMr. Michael B. Brophy M.B.A. (Age 44)Chief Financial Officer Comp: $611.35kMr. Daniel Rabinowitz L.L.M. (Age 55)Secretary & Chief Legal Officer Comp: $566.03kMr. John FeskoPresident & Chief Business OfficerMr. Jonathan Sheena M.Eng. (Age 51)Co-Founder & Director Comp: $293.91kMs. Olesya A. Anisimova CPAChief Accounting OfficerMr. Rishi KackerChief Technology OfficerMr. Eric A. EvansChief Scientific OfficerMr. Jerry DiffleyChief Compliance & Privacy OfficerMore ExecutivesKey CompetitorsFresenius Medical CareNYSE:FMSQuest DiagnosticsNYSE:DGXPACS GroupNYSE:PACSOption Care HealthNASDAQ:OPCHSotera HealthNASDAQ:SHCView All CompetitorsInsiders & InstitutionsSanctuary Advisors LLCBought 3,513 shares on 9/5/2024Ownership: 0.003%Gordian Capital Singapore Pte LtdBought 2,630 shares on 8/30/2024Ownership: 0.002%Maven Securities LTDBought 2,000 shares on 8/29/2024Ownership: 0.002%Cetera Investment AdvisersSold 2,889 shares on 8/22/2024Ownership: 0.014%Truist Financial CorpSold 3,115 shares on 8/21/2024Ownership: 0.033%View All Insider TransactionsView All Institutional Transactions NTRA Stock Analysis - Frequently Asked Questions How have NTRA shares performed this year? Natera's stock was trading at $62.64 on January 1st, 2024. Since then, NTRA stock has increased by 80.2% and is now trading at $112.90. View the best growth stocks for 2024 here. How were Natera's earnings last quarter? Natera, Inc. (NASDAQ:NTRA) announced its earnings results on Thursday, August, 8th. The medical research company reported ($0.30) EPS for the quarter, beating analysts' consensus estimates of ($0.69) by $0.39. The business's quarterly revenue was up 58.1% compared to the same quarter last year. What is Steve Chapman's approval rating as Natera's CEO? 158 employees have rated Natera Chief Executive Officer Steve Chapman on Glassdoor.com. Steve Chapman has an approval rating of 91% among the company's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. When did Natera IPO? Natera (NTRA) raised $101 million in an initial public offering on Thursday, July 2nd 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers. Who are Natera's major shareholders? Top institutional investors of Natera include Fred Alger Management LLC (4.29%), Farallon Capital Management LLC (3.63%), Massachusetts Financial Services Co. MA (1.95%) and Duquesne Family Office LLC (1.61%). Insiders that own company stock include Matthew Rabinowitz, Jonathan Sheena, Daniel Rabinowitz, Steven Leonard Chapman, Solomon Moshkevich, John Fesko, Michael Burkes Brophy, Herm Rosenman, James Healy, Gail Boxer Marcus, Rowan E Chapman, Robert Alan Schueren and Roelof Botha. View institutional ownership trends. How do I buy shares of Natera? Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Natera own? Based on aggregate information from My MarketBeat watchlists, some other companies that Natera investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV) and Aegean Marine Petroleum Network (ANW). This page (NASDAQ:NTRA) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Natera, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Natera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.